Prof Rammensee speaks with ecancer at WIN 2017 about assessing the human leukocyte antigen (HLA) rearrangements of cancer patients to determine new targets for therapies.

He summarises the 'ligandome' and its role in directing T cell response, noting mutation-high tumours responding more to checkpoint immunotherapy, and describes how peptides derived from ligand assays could help design cancer vaccines.

свернуть